Last updated: 11/07/2018 18:27:52
A Multicentre Double-Blind Crossover Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multicentre Double-Blind Crossover Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens
Trial description: A Multicentre Double-Blind Crossover Study to Compare the Efficacy and Safety of GR38032F with Metoclopramide in the Prophylaxis of Acute Nausea and Vomiting Induced by Cisplatin-Containing Cancer Chemotherapy Regimens
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. a multicenter, randomized, double-blind, crossover study. De Mulder, P. H., Seynaeve, C., Vermorken, J. B., van Liessum, P. A., Mols-Jevdevic, S., Allman, E. L., Beranek, P., and Verweij, J. Ann Intern Med 90; 113 (11):834-40,
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website